Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML

Blood (2023) 142 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2023-189259

Published: 2023

Journal Articles

The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy

Gerard Hilinski, Blaise Stearns, Sandip Vibhute, Tiffany Hughes, Susheela Tridandapani, Megan E. Johnstone, Thomas E. Goodwin, Jeffrey Patrick, Chad E. Bennett, Don Benson, John C. Byrd, Ola A. Elgamal, Erin K. Hertlein

Blood (2023) 142 (Supplement 1): 4692.

https://doi.org/10.1182/blood-2023-189238

Published: 2023

Journal Articles

Genome-Wide Methylome and Transcriptome Profiling of Acute Myeloid Leukemia Derived Bone Marrow Mesenchymal Cells Identify Age Group Specific Biological Pathway Dysregulation in the Bone Marrow Microenvironment of AML

Amina Abdul-Aziz, James R. Lerma, Amy Kovacs, Shesh N. Rai, Jianmin Pan, Liang Niu, Alice Mims, Christopher C. Oakes, John C. Byrd, Erin K. Hertlein

Blood (2023) 142 (Supplement 1): 5620.

https://doi.org/10.1182/blood-2023-189973

Published: 2023

Journal Articles

A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

Blood (2023) 142 (Supplement 1): 4153.

https://doi.org/10.1182/blood-2023-189266

Published: 2023

Journal Articles

Development of a Fully Immunocompetent Adoptive Transfer In Vivo Model of Npm1 cA ;Idh2 R140Q ;Flt3 ITD AML

Chia Sharpe, Mariah Johnson, Sydney Fobare, Ola A. Elgamal, Bonnie K. Harrington, Allison Mustonen, Kinsey Bryant, Carolyn Cheney, James R. Lerma, Jean Truxall, Casie Furby, Marissa Long, Kaytlynn Fyock, Alan Shih, Ross L Levine, Erin K. Hertlein, John C. Byrd

Blood (2023) 142 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2023-189975

Published: 2023

Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3221.

https://doi.org/10.1182/blood.V128.22.3221.3221

Published: 2016

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L Chen, David M Lucas, PhD, Nikhil Gupta, Jessica MacMurray, Virginia M. Goettl, DVM , PhD, Amy M. Lehman, MAS, Amy J. Johnson, PhD, John C Byrd, MD

Blood (2015) 126 (23): 1248.

https://doi.org/10.1182/blood.V126.23.1248.1248

Published: 2015

Journal Articles

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Yo-Ting Tsai, MS, Gerard Lozanski, MD, Amy M. Lehman, MAS, Ellen Sass, Erin K. Hertlein, PhD, Santosh Salunke, Ching-Shih Chen, PhD, Michael R. Grever, MD, John C. Byrd, MD, David M. Lucas, PhD

Blood (2015) 126 (23): 2477.

https://doi.org/10.1182/blood.V126.23.2477.2477

Published: 2015

Journal Articles

The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia

Cecelia R Miller, MS, Amy S. Ruppert, MAS, Kevin Coombes, PhD, Amy M. Lehman, MAS, James S. Blachly, MD, David M. Lucas, PhD, Michael R. Grever, MD, Martin S Tallman, MD, Ian W. Flinn, MD PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Deepa Sampath, PhD, John C Byrd, MD, Erin K. Hertlein, PhD

Blood (2015) 126 (23): 2911.

https://doi.org/10.1182/blood.V126.23.2911.2911

Published: 2015

Journal Articles

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

Daphne Guinn, Amy S. Ruppert, MAS, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Amber L. Gordon, Thomas S. Lin, MD PhD, Richard A. Larson, Guido Marcucci, MD, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 3297.

https://doi.org/10.1182/blood.V124.21.3297.3297

Published: 2014

Journal Articles

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

Ta-Ming Liu, YongHua Ling, Mitch A. Phelps, PhD, Jennifer A. Woyach, MD, Erin K Hertlein, PhD, William H. Towns, Jessica MacMurray, Santosh B. Salunke, PhD, Ching-Shih Chen, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2013) 122 (21): 2523.

https://doi.org/10.1182/blood.V122.21.2523.2523

Published: 2013

Journal Articles

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Kami Maddocks, MD, Erin K Hertlein, PhD, Joseph M. Flynn, DO, MPH, Leslie A Andritsos, MD, Amy J. Wagner, Timothy L. Chen, Mitch A. Phelps, PhD, Michael R. Grever, MD, Amy J. Johnson, PhD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH

Blood (2012) 120 (21): 1800.

https://doi.org/10.1182/blood.V120.21.1800.1800

Published: 2012

Journal Articles

Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.

Lapo Alinari, MD., Ph.D., Fengting Yan, M.D., Ph.D., Porsha Smith, John T. Patton, Carl Quinion, Bo Yu, Ph.D, Christian Tyler Earl, Mark E Lustberg, MD, PhD, Lynda Villagomez, Erin K Hertlein, PhD, John C. Byrd, MD, Leona Ayers, MD, Tasneem Motiwala, PhD, Sarmila Majumder, PhD, Chenglong Li, Ph.D., Said Sif, Ph.D., Samson T. Jacob, PhD, Robert A. Baiocchi, M.D., Ph.D.

Blood (2012) 120 (21): 2378.

https://doi.org/10.1182/blood.V120.21.2378.2378

Published: 2012

Journal Articles

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L. Chen, Rainer Claus, MD, Christoph Plass, PhD, Amy Lehman, David Jarjoura, PhD, Kami Maddocks, MD, Jeffrey A. Jones, MD, MPH, David M. Lucas, PhD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 1362.

https://doi.org/10.1182/blood.V120.21.1362.1362

Published: 2012

Journal Articles

The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response,

Sneha V. Gupta, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Ellen J. Sass, Melanie E. Davis, John C. Byrd, MD, David M. Lucas, PhD

Blood (2011) 118 (21): 3510.

https://doi.org/10.1182/blood.V118.21.3510.3510

Published: 2011

Journal Articles

Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease.

Erin K Hertlein, PhD, Lianbo Yu, Jianying Zhang, Amy J. Johnson, PhD, David Lucas, PhD, Guido Marcucci, MD, David Jarjoura, John C. Byrd, MD

Blood (2010) 116 (21): 3642.

https://doi.org/10.1182/blood.V116.21.3642.3642

Published: 2010

Journal Articles

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Lapo Alinari, MD, Beth Christian, MD, Bo Yu, Jungook Shin, Erin K Hertlein, PhD, Rosa Lapalombella, PhD, Fengting Yan, MD, PhD, Gregory Lesinski, PhD, Xiaoli Zhang, PhD, Gerard Lozanski, MD, Natarajan Muthusamy, PhD, David M. Goldenberg, ScD, MD, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD

Blood (2009) 114 (22): 1694.

https://doi.org/10.1182/blood.V114.22.1694.1694

Published: 2009

Journal Articles

Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells.

Erin K Hertlein, PhD, Georgia Triantafillou, Joshua Hessler, Xiaoli Zhang, David Jarjoura, David M. Lucas, PhD, Robert J Lee, Natarajan Muthusamy, PhD, David M Goldenberg, ScD, MD, John C. Byrd, MD

Blood (2009) 114 (22): 721.

https://doi.org/10.1182/blood.V114.22.721.721

Published: 2009

Journal Articles

The HSP90 Inhibitor 17-DMAG Targets NF-κB to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model.

Erin K Hertlein, PhD, Thomas S Lin, MD, PhD, Wagner J Amy, Towns H William, II, Virginia M Goettl, Xiaoli Zhang, David Jarjoura, Chelsey A Raymond, Derek A West, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2009) 114 (22): 732.

https://doi.org/10.1182/blood.V114.22.732.732

Published: 2009

NARROW

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML

The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy

Genome-Wide Methylome and Transcriptome Profiling of Acute Myeloid Leukemia Derived Bone Marrow Mesenchymal Cells Identify Age Group Specific Biological Pathway Dysregulation in the Bone Marrow Microenvironment of AML

A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

Development of a Fully Immunocompetent Adoptive Transfer In Vivo Model of Npm1 cA ;Idh2 R140Q ;Flt3 ITD AML

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response,

Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease.

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells.

The HSP90 Inhibitor 17-DMAG Targets NF-κB to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only